Investor Alert

EyePoint Pharmaceuticals Inc.



After Hours

 --Quotes are delayed by 20 min

May 26, 2023, 7:57 p.m.





+0.03 +0.51%


Volume 9,866

Quotes are delayed by 20 min


Previous close

$ 5.93

$ 5.93


0.00 0.00%

Day low

Day high




52 week low

52 week high




Annual Financials for EyePoint Pharmaceuticals Inc.

Fiscal year is January-December. All values USD millions. 20182019202020212022 5-year trend
Sales/Revenue 5.86M20.37M34.44M36.94M41.4M
Cost of Goods Sold (COGS) incl. D&A -5.15M8.28M10.64M10.38M
COGS excluding D&A -2.54M5.64M7.87M7.93M
Depreciation & Amortization Expense 2.65M2.6M2.65M2.77M2.45M
Depreciation 194,000144,000189,000311,000396,000
Amortization of Intangibles 2.46M2.46M2.46M2.46M2.05M
Gross Income -15.22M26.15M26.3M31.03M
20182019202020212022 5-year trend
SG&A Expense 52.32M63.08M63.44M81.58M109.97M
Research & Development 20.82M15.37M17.42M28.5M49.64M
Other SG&A 31.5M47.71M46.02M53.08M60.32M
Other Operating Expense -----
Unusual Expense 18.89M3.81M905,000(2.07M)22.26M
EBIT after Unusual Expense (68M)(51.67M)(38.2M)(53.21M)(101.2M)
Non Operating Income/Expense (18.89M)----
Non-Operating Interest Income 734,0001.05M58,000292,0002.13M
Equity in Affiliates (Pretax) -----
Interest Expense 3.28M6.18M7.26M5.5M3.19M
Gross Interest Expense 3.28M6.18M7.26M5.5M3.19M
Interest Capitalized -----
Pretax Income (89.44M)(56.79M)(45.39M)(58.42M)(102.25M)
Income Tax -----
Income Tax - Current Domestic -----
Income Tax - Current Foreign -----
Income Tax - Deferred Domestic -----
Income Tax - Deferred Foreign -----
Income Tax Credits -----
Equity in Affiliates -----
Other After Tax Income (Expense) -----
Consolidated Net Income (89.44M)(56.79M)(45.39M)(58.42M)(102.25M)
Minority Interest Expense -----
Net Income (89.44M)(56.79M)(45.39M)(58.42M)(102.25M)
Extraordinaries & Discontinued Operations -----
Extra Items & Gain/Loss Sale Of Assets -----
Cumulative Effect - Accounting Chg -----
Discontinued Operations -----
Net Income After Extraordinaries (89.44M)(56.79M)(45.39M)(58.42M)(102.25M)
Preferred Dividends -----
Net Income Available to Common (89.44M)(56.79M)(45.39M)(58.42M)(102.25M)
EPS (Basic) (10.50)(5.44)(3.54)(2.03)(2.74)
Basic Shares Outstanding 8.51M10.43M12.84M28.76M37.32M
EPS (Diluted) (10.50)(5.44)(3.54)(2.03)(2.74)
Diluted Shares Outstanding 8.51M10.43M12.84M28.76M37.32M
EBITDA (46.47M)(45.26M)(34.64M)(52.51M)(76.49M)
Link to MarketWatch's Slice.